BioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes

Dow Jones

昨天

By Denny Jacob

BioNTech SE posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines.

The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros ($281.1 million), or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros ($496.1 million), or 1.88 euros a share, in the prior-year period.

Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros.

The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year.

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin.

BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

March 10, 2025 07:39 ET (11:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2518247060"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518247060\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518247060?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-10 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518247060","market":"other","top_or_hot":-1,"title":"BioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines. \n</p>\n<p>\n  The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros ($281.1 million), or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros ($496.1 million), or 1.88 euros a share, in the prior-year period. \n</p>\n<p>\n  Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros. \n</p>\n<p>\n  The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year. \n</p>\n<p>\n  \"We expect 2025 to be a data-rich year with multiple important updates from our priority programs,\" said Chief Executive Ugur Sahin. \n</p>\n<p>\n  BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 07:39 ET (11:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-10 19:39</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines. \n</p>\n<p>\n  The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros ($281.1 million), or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros ($496.1 million), or 1.88 euros a share, in the prior-year period. \n</p>\n<p>\n  Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros. \n</p>\n<p>\n  The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year. \n</p>\n<p>\n  \"We expect 2025 to be a data-rich year with multiple important updates from our priority programs,\" said Chief Executive Ugur Sahin. \n</p>\n<p>\n  BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 07:39 ET (11:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2518247060","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518247060","pubTimestamp":1741606740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BioNTech SE posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines.The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros , or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros , or 1.88 euros a share, in the prior-year period.Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros.The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year.\"We expect 2025 to be a data-rich year with multiple important updates from our priority programs,\" said Chief Executive Ugur Sahin.BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"随着Covid-19疫苗需求减弱，BioNTech SE第四季度利润下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"By Denny Jacob \n\n\n \n\n\nBioNTech SE posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines. \n\n\n  The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros ($281.1 million), or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros ($496.1 million), or 1.88 euros a share, in the prior-year period. \n\n\n  Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros. \n\n\n  The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year. \n\n\n  \"We expect 2025 to be a data-rich year with multiple important updates from our priority programs,\" said Chief Executive Ugur Sahin. \n\n\n  BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 07:39 ET (11:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}